Judge Finds No Direct Infringement In Strattera Suit

Law360, New York (May 21, 2009, 12:00 AM EDT) -- A federal judge has ruled that several generic-drug makers do not directly infringe a patent related to Eli Lilly & Co.'s drug Strattera, which is used to treat attention deficit/ hyperactivity disorder, because the patent covers a method rather than a drug.

Judge Dennis M. Cavanaugh of the U.S. District Court for the District of New Jersey ruled Wednesday that the generic companies — Sun Pharmaceutical Industries Ltd., Actavis Elizabeth LLC, Sandoz Inc., Mylan Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd. and Teva Pharmaceuticals USA Inc....
To view the full article, register now.